Summary

KEY FINDINGS
The India Alzheimer’s disease therapeutics & diagnostics market is projected to grow at a CAGR of 6.40% over the forecast period of 2024-2032. The market was valued at $221.06 million in 2023 and is expected to reach a revenue of $388.22 million by 2032.
MARKET INSIGHTS
The India Alzheimer’s disease therapeutics & diagnostics market is influenced by the increasing prevalence of Alzheimer’s disease, especially as the aging population grows. As dementia-related conditions become more common, the demand for both diagnostic tools and treatments is rising. The aging demographic in India has led to a higher number of Alzheimer’s cases, which has heightened the need for early diagnosis and effective management options. This shift is fostering greater awareness and prompting the healthcare system to prioritize better detection and treatment solutions.
Advances in diagnostic technologies, such as in-vitro diagnostics and the use of computed tomography (CT) in Alzheimer’s detection, are playing a crucial role in this market. In-vitro diagnostics, especially those based on biomarkers, allow for earlier detection of Alzheimer’s, which is key for slowing disease progression. CT scans are also being increasingly used to detect changes in brain structure, providing valuable insights into the presence of Alzheimer’s. These improvements in diagnostic methods enable healthcare providers to offer timely interventions and better manage the disease.
Investment in research and development, particularly in biomarkers for early detection, is another driving force in the market. Biomarkers can identify Alzheimer’s before clinical symptoms appear, improving early intervention and treatment outcomes. As R&D efforts in this area intensify, India is contributing to global advancements in Alzheimer’s diagnostics. The development of these biomarkers is expected to improve diagnostic accuracy and open up new possibilities for personalized treatment approaches.
The increasing demand for personalized medicine is also shaping the growth of the therapeutics sector. Personalized medicine offers tailored treatments based on individual patient profiles, such as genetic information and disease progression. This approach ensures more effective and targeted treatment for Alzheimer’s patients. As India adopts personalized therapies, pharmaceutical companies are focusing on developing new drugs to meet this demand, offering more options to slow the disease and manage symptoms.
SEGMENTATION ANALYSIS
The India Alzheimer’s disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further divided into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer’s disease, and other diagnostics).
Cholinesterase inhibitors are a class of drugs commonly used in the treatment of Alzheimer's disease to help manage symptoms by improving communication between nerve cells in the brain. Further, these drugs work by inhibiting the enzyme acetylcholinesterase, which breaks down acetylcholine, a neurotransmitter essential for memory and learning. By increasing the levels of acetylcholine, cholinesterase inhibitors can help alleviate some cognitive symptoms associated with Alzheimer's. These symptoms include memory loss, confusion, and difficulty with thinking and reasoning.
The most widely prescribed cholinesterase inhibitors for Alzheimer's disease include Donepezil, Rivastigmine, and Galantamine. These medications are typically used in the early to moderate stages of the disease and can offer symptomatic relief, though they do not stop or slow the disease’s progression. Cholinesterase inhibitors are often considered a first-line treatment, and their effectiveness can vary between individuals. While they can provide temporary improvement in cognitive function or slow its decline, they do not address the underlying causes of Alzheimer's disease.
COMPETITIVE INSIGHTS
Some of the eminent companies operating in the India Alzheimer’s disease therapeutics & diagnostics market include Pfizer Inc, Eli Lilly and Company, F Hoffmann-La Roche AG, etc.
Pfizer Inc, a US-based biopharmaceutical company headquartered in New York, was founded in 1849. It focuses on discovering, developing, manufacturing, and marketing medicines, vaccines, and consumer healthcare products. Pfizer’s portfolio addresses a wide range of conditions, including respiratory, cardiovascular, and metabolic diseases, cancer, infections, inflammation, neurological issues, and more. The company operates in the Americas, Asia-Pacific, Europe, and the Middle East & Africa. Pfizer continues to innovate and expand its offerings to treat various health challenges worldwide.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE INDIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GROWING R&D INVESTMENT IN THE BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.5.2. INCREASING DEMAND FOR THE PERSONALIZED MEDICINES
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS
3.2. KEY DRIVERS
3.2.1. INCREASE IN ALZHEIMER’S DISEASE CASES
3.2.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
3.2.3. GROWTH IN THE NUMBER OF DRUGS UNDER DEVELOPMENT
3.2.4. EXPANSION OF THE ELDERLY POPULATION
3.3. KEY RESTRAINTS
3.3.1. LIMITED AVAILABILITY OF SURROGATE MARKERS
3.3.2. LATE-STAGE DRUG FAILURES
3.3.3. STRICT GOVERNMENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
4.1.2. USAGE OF COMPUTED TOMOGRAPHY IN THE DIAGNOSTICS OF ALZHEIMER’S DISEASE
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR INDIA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. R&D
4.6.2. RAW MATERIAL
4.6.3. MANUFACTURING
4.6.4. WHOLESALERS/DISTRIBUTORS/RETAILERS
4.6.5. END-USER
4.7. KEY BUYING CRITERIA
4.7.1. PRICE
4.7.2. EFFICIENCY
4.7.3. SAFETY
4.8. ETYMOLOGY OF THE INDIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
4.9. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
5. MARKET BY PRODUCT
5.1. THERAPEUTICS
5.1.1. CHOLINESTERASE INHIBITORS
5.1.2. NMDA RECEPTOR ANTAGONISTS
5.1.3. OTHER THERAPEUTICS
5.2. DIAGNOSTICS
5.2.1. BRAIN IMAGING
5.2.2. CSF TEST FOR ALZHEIMER’S DISEASE
5.2.3. OTHER DIAGNOSTICS
6. COMPETITIVE LANDSCAPE
6.1. KEY STRATEGIC DEVELOPMENTS
6.1.1. MERGERS & ACQUISITIONS
6.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
6.1.3. PARTNERSHIPS & AGREEMENTS
6.1.4. BUSINESS EXPANSIONS & DIVESTITURES
6.2. COMPANY PROFILES
6.2.1. BIOGEN INC
6.2.1.1. COMPANY OVERVIEW
6.2.1.2. PRODUCT LIST
6.2.1.3. STRENGTHS & CHALLENGES
6.2.2. ELI LILLY AND COMPANY
6.2.2.1. COMPANY OVERVIEW
6.2.2.2. PRODUCT LIST
6.2.2.3. STRENGTHS & CHALLENGES
6.2.3. F HOFFMANN-LA ROCHE AG
6.2.3.1. COMPANY OVERVIEW
6.2.3.2. PRODUCT LIST
6.2.3.3. STRENGTHS & CHALLENGES
6.2.4. NOVARTIS AG
6.2.4.1. COMPANY OVERVIEW
6.2.4.2. PRODUCTS LIST
6.2.4.3. STRENGTHS & CHALLENGES
6.2.5. JOHNSON & JOHNSON
6.2.5.1. COMPANY OVERVIEW
6.2.5.2. PRODUCT LIST
6.2.5.3. STRENGTHS & CHALLENGES
6.2.6. MERCK & CO INC
6.2.6.1. COMPANY OVERVIEW
6.2.6.2. PRODUCT LIST
6.2.6.3. STRENGTHS & CHALLENGES
6.2.7. PFIZER INC
6.2.7.1. COMPANY OVERVIEW
6.2.7.2. PRODUCT LIST
6.2.7.3. STRENGTHS & CHALLENGES